Allergan has revealed positive Phase 3 data on its oral calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant, illustrating the therapy’s strength compared to placebo in the acute treatment of migraine.
The data revealed that both 25mg and 50mg doses of ubrogepant displayed “statistically significant higher response rates” for pain freedom at two hours compared to placebo, with rates standing at 21.8% and 20.7% versus 14.3%.
